Biden to Launch “FedNOW” [Move Your Money Now]

Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...

Get your free information kit NOW, before it's too late.

Mark Schoenberg Biography and Net Worth

Insider of UroGen Pharma

Mark is an internationally recognized expert in the treatment of urothelial cancer and an active investigator and contributor to peer-reviewed literature in urologic oncology.

Mark has held prominent roles at several major universities, including the Bernard Schwartz Distinguished Professor of Urologic Oncology at Johns Hopkins University from 2005 to 2014.

Under the auspices of The American Cancer Society, Mark completed his fellowship in urologic oncology at The James Buchanan Brady Urological Institute of Johns Hopkins University. He served as a resident in surgery and urology at the Hospital of The University of Pennsylvania and received his doctor of medicine from The University of Texas (Houston) and his undergraduate degree from Yale University.

Mark is a founding member of the scientific advisory board of The Bladder Cancer Advocacy Network.

What is Mark Schoenberg's net worth?: The estimated net worth of Mark Schoenberg is at least $1.99 million as of March 18th, 2024. Dr. Schoenberg owns 139,437 shares of UroGen Pharma stock worth more than $1,985,583 as of April 17th. This net worth evaluation does not reflect any other assets that Dr. Schoenberg may own. Additionally, Dr. Schoenberg receives an annual salary of $579,500.00 as Insider at UroGen Pharma. Learn More about Mark Schoenberg's net worth.
How old is Mark Schoenberg?: Dr. Schoenberg is currently 66 years old. There are 3 older executives and no younger executives at UroGen Pharma. Learn More on Mark Schoenberg's age.
What is Mark Schoenberg's salary?: As the Insider of UroGen Pharma Ltd., Dr. Schoenberg earns $579,500.00 per year. There are 2 executives that earn more than Dr. Schoenberg. The highest earning executive at UroGen Pharma is Ms. Elizabeth A. Barrett, President, CEO & Director, who commands a salary of $1,120,000.00 per year. Learn More on Mark Schoenberg's salary.
How do I contact Mark Schoenberg?: The corporate mailing address for Dr. Schoenberg and other UroGen Pharma executives is 400 Alexander Park, Princeton NJ, 08540. UroGen Pharma can also be reached via phone at (646) 768-9780 and via email at [email protected]. Learn More on Mark Schoenberg's contact information.
Has Mark Schoenberg been buying or selling shares of UroGen Pharma?: Mark Schoenberg has not been actively trading shares of UroGen Pharma in the last ninety days. Most recently, Mark Schoenberg sold 12,000 shares of the business's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $14.05, for a transaction totalling $168,600.00. Following the completion of the sale, the insider now directly owns 139,437 shares of the company's stock, valued at $1,959,089.85. Learn More on Mark Schoenberg's trading history.
Who are UroGen Pharma's active insiders?: UroGen Pharma's insider roster includes Elizabeth Barrett (CEO), Molly Henderson (CFO), Mark Schoenberg (Insider), and Jason Smith (General Counsel). Learn More on UroGen Pharma's active insiders.
Are insiders buying or selling shares of UroGen Pharma?: In the last twelve months, insiders at the sold shares 4 times. They sold a total of 24,582 shares worth more than $375,266.68. The most recent insider tranaction occured on March, 18th when insider Mark Schoenberg sold 12,000 shares worth more than $168,600.00. Insiders at UroGen Pharma own 11.1% of the company. Learn More about insider trades at UroGen Pharma.
Information on this page was last updated on 3/18/2024.

Mark Schoenberg Insider Trading History at UroGen Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2024	Sell	12,000	$14.05	$168,600.00	139,437
1/31/2024	Sell	3,789	$15.74	$59,638.86	149,423
1/31/2023	Sell	1,900	$10.12	$19,228.00	146,879
10/31/2022	Sell	258	$11.85	$3,057.30	23,950
8/1/2022	Sell	259	$7.81	$2,022.79	23,708
4/30/2022	Sell	254	$6.62	$1,681.48	23,467
1/31/2022	Sell	1,374	$7.58	$10,414.92
1/26/2022	Sell	111	$8.09	$897.99
11/18/2021	Buy	160	$13.10	$2,096.00
11/1/2021	Sell	258	$17.16	$4,427.28
10/27/2021	Sell	107	$16.32	$1,746.24
8/2/2021	Sell	243	$15.64	$3,800.52
7/26/2021	Sell	103	$15.30	$1,575.90
4/26/2021	Sell	89	$19.63	$1,747.07	20,964
1/31/2021	Sell	1,076	$22.07	$23,747.32	21,831
1/26/2021	Sell	100	$22.12	$2,212.00	19,931
12/4/2020	Sell	662	$19.85	$13,140.70	20,385
10/26/2020	Sell	101	$20.95	$2,115.95	19,444
9/4/2020	Sell	348	$20.20	$7,029.60	19,584
7/27/2020	Sell	70	$23.51	$1,645.70	18,613
6/4/2020	Sell	349	$27.51	$9,600.99	18,753
4/27/2020	Sell	70	$24.35	$1,704.50	17,781
1/27/2020	Sell	322	$29.15	$9,386.30	9,499
11/19/2019	Buy	1,960	$28.17	$55,213.20
3/21/2019	Buy	272	$37.01	$10,066.72
3/6/2019	Sell	1,991	$37.30	$74,264.30

Mark Schoenberg Buying and Selling Activity at UroGen Pharma

UroGen Pharma Company Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Today's Range

Now: $14.24

$14.02

$14.66

50 Day Range

MA: $16.38

$12.95

$19.33

2 Week Range

Now: $14.24

$8.69

$24.13

Volume

187,493 shs

Average Volume

438,425 shs

Market Capitalization

$333.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Biden to Launch “FedNOW” [Move Your Money Now]

From Priority Gold | Ad

Get your free information kit NOW, before it's too late.

Mark Schoenberg Biography and Net Worth

What is Mark Schoenberg's net worth?

How old is Mark Schoenberg?

What is Mark Schoenberg's salary?

How do I contact Mark Schoenberg?

Has Mark Schoenberg been buying or selling shares of UroGen Pharma?

Who are UroGen Pharma's active insiders?

Are insiders buying or selling shares of UroGen Pharma?